This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Clinical Experience -
Sildenafil versus continuous positive airway pressure for
erectile dysfunction in men with obstructive sleep apnea: a
comparative study of their efficacy and safety and the patient's
satisfaction with treatment
Petros Perimenis1, Kyriakos
Karkoulias2, Angelis
Konstantinopoulos1, Paraskevi P.
Perimeni1, George Katsenis1,
Anastasios Athanasopoulos1, Konstantinos
Spyropoulos2
Departments of 1Urology and
2Pneumonology, University Hospital of Patras, Patras 26500, Greece
Abstract
Aim: To assess the efficacy of sildenafil and continuous positive airway pressure (CPAP) in the treatment of
concurrent erectile dysfunction (ED) with obstructive sleep apnea (OSA), and to gauge the level of treatment satisfaction in
patients and their partners. Methods: Forty men were treated for 12 weeks with sildenafil 100 mg (20 men) or CPAP
during nighttime sleep (20 men). Treatment efficacy was assessed by the rate of successful intercourse attempts,
and satisfaction with treatment was assessed by patients' and partners' answers to question 1 of the Erectile
Dysfunction Inventory of Treatment
Satisfaction. Results: Under sildenafil, 128 of 249 (51.4%) intercourse attempts
were successful; under CPAP, 51 of 193 (26.9%) attempts were successful
(cP < 0.001). Erectile function was
improved in both groups. After sildenafil and CPAP treatment, the mean International Index for Erectile Function
domain scores were 14.3 and 10.8, respectively
(bP = 0.025), compared to 7.8 and 7 at baseline, respectively. CPAP
and sildenafil were well tolerated. Sporadic episodes of nasal dryness under CPAP and transient headache and flushing
under sildenafil were not significant. Fifty percent of patients treated with sildenafil and 25% with CPAP were
satisfied with the treatment, and their partners were equally satisfied. The satisfaction scores for both patients and
partners under sildenafil were superior to those under CPAP
(cP < 0.002). Conclusion:
Both sildenafil 100 mg and CPAP, used separately, had positive therapeutic impact but sildenafil was superior. Patients and their partners were
more satisfied with sildenafil for the treatment of ED. However, because of the high proportion of dissatisfied men
and partners, new therapeutic agents or a combination of the two methods must be studied
further. (Asian J Androl 2007 Mar; 9: 259_264)
Keywords: obstructive sleep apnea; erectile dysfunction; continuous positive airway pressure; sildenafil
Correspondence to: Dr Petros Perimenis, Medical School, University of Patras, 26500 Rio, Patras, Greece.
Tel/Fax: +30-2610-994-668
E-mail: petperim@upatras.gr
Received 2005-01-31 Accepted 2005-04-28
DOI: 10.1111/j.1745-7262.2006.00085.x
1 Introduction
Sleep apnea is a common disorder which causes a
cessation or reduction of breathing during sleep, with
consequent blood oxygen desaturation and sleep fragmentation.
The disease affects almost every system of the body and
results in daytime somnolence and neurocognitive
defects [1]. Among its sequelae, erectile dysfunction (ED)
has been reported as an early sign of nerve involvement.
Fanfulla et al. [2] suggested that the impairment of
sacral segment function in obstructive sleep apnea (OSA)
patients is related to the development of signs of ED.
However, Margel et al. [3] showed that only severe OSA
is clearly associated with ED, and suggested morning
tiredness and respiratory disturbance index (RDI) as
predictive factors. Although the etiologic association
between OSA and ED remains controversial, sexual
problems are common among men with sleep disorders.
Guilleminault et al. [4] reported an incidence of 48% of
sexual problems among men aged 25_65 years with sleep
apnea. Supporting these findings, studies of nocturnal
penile tumescence in men with ED revealed a high rate
of sleep disorders ranging from 44% to 61% [5, 6].
A dearth of nitric oxide (NO) has been implicated for
the development of the OSA consequences [7]. NO
deficiency and obstructive apnea are reportedly inseparable
conditions [8]. ED, as a result of endothelial dysfunction,
is often related with diabetes mellitus, atherosclerosis,
hypertension and coronary artery disease; almost all are
long-term complications of OSA. Logically, the
association between OSA and ED might be explained by the
impairment of NO vasoprotective function due to the
respiratory disturbances during nighttime sleep.
Nasal continuous positive airway pressure (CPAP)
is the treatment of choice for OSA and its sequelae [9].
Its efficacy has also been studied in the treatment of
associated ED [10, 11]. The advent of sildenafil citrate,
a PDE 5 inhibitor, revolutionized the treatment of ED
[12, 13]. The initial results of its effectiveness in men
with ED and OSA were promising [11]. In the present
study we assessed and compared the efficacy of CPAP
and sildenafil in the treatment of ED in men with OSA,
and also assessed patients' and their partners'
satisfaction with the treatment.
2 Patients and methods
The trial was prospective and randomized. It
included 40 naive, consecutive cases of men with OSA
who were found to suffer from concurrent ED. The sources of these patients were the outpatient clinic for
sleep disorders and the laboratory for the study of ED of
the Departments of Pneumonology and Urology of the
University Hospital of Patras. At the sleep laboratory,
they were evaluated for two consecutive nights for the
purposes of diagnosis and one additional night for the
therapeutic titration. Surface electrodes were applied to
obtain an electroencephalogram (C3_C4, A1_A2, O3_O4), an electrooculogram, a mental electromyogram and
an electrocardiogram. Expiratory airflow was detected
by a nasal catheter. Any movements of the chest and
abdomen wall were also examined. All of these variables
were recorded on a polysomnograph that was synchronized to a data acquisition system (Somnostar A Series,
SensorMedics, Bilthoven, The Netherlands). A fiberoptic
oximeter to the polysomnography study system was used
to measure the arterial oxygen saturation. Sleep stages
and events were scored manually according to standard
criteria. Apnea was defined as the complete cessation of
airflow for at least 10 s and hypopnea as the reduction in
airflow by at least 50% for 10 s or more. The number of
apnea and hypopnea episodes per hour of sleep was measured by the RDI. An index of at least six
respiratory events (apneas and hypopneas) per hour of sleep
was required for the diagnosis of OSA and inclusion in
this study.
Patients were asked to answer questions 3 and 4 of
the International Index of Erectile Function (IIEF)
questionnaire (see Appendix I). When the score was 4 or
less for both questions they were referred for andrologic
evaluation if they agreed. Within a 4-week baseline
period a detailed history was taken, the men were
physically examined, underwent laboratory, biochemical and
hormonal tests, and completed an IIEF questionnaire
form. Men who initially complained of ED, except for
the standard andrologic evaluation mentioned above, were
asked for sleep disturbances, somnolence and snoring,
and referred to the sleep laboratory for monitoring when
appropriate.
Patients were excluded from the study if they had a
deformity of their external genitals, if they took nitrates,
if they were already being treated for ED, if they had any
hormonal deficiency, or if they had not been in a stable
relationship for at least 6 months. Men who agreed to be
treated signed a consent form and were randomly allocated, by a computer generation table of random
numbers, to receive sildenafil 100 mg orally on demand,
approximately 1 h prior to intercourse (20 men) or to be
treated with CPAP in therapeutic levels at home during
nighttime sleep (20 men) without taking any medication
for ED. The duration of treatment was 12 weeks. The
nature of the diseases and the details and goals of the
treatment were thoroughly explained to the couples. They
were encouraged to attempt sexual intercourse and were
instructed on manual stimulation during foreplay. They
were also asked to report immediately after intercourse
on the success of the attempt in a standardized event-log
(Sexual Encounter Profile). Men were thoroughly
instructed on how to take the medication or use the device
and they were ordered to immediately refer any adverse
effect. They were regularly assessed every 4 weeks and
finally evaluated in detail at the end of the treatment period,
when they completed an IIEF form and replied to the
first question of the Erectile Dysfunction Inventory of
Treatment Satisfaction (EDITS, patient and partner
version) [14]. The patient and his partner were
considered "satisfied with the treatment" if the answer scored
4 or 5 (see Appendix II). Patients continued to receive
medications regularly for their concomitant diseases
throughout the study.
The primary outcomes of the study were the
percentage of successful intercourse attempts and the
satisfaction levels of the patients and partners with the treatment
for ED. The secondary outcomes were the changes in
IIEF domain scores and related adverse
events. Statistical analysis was performed using
paireda and unpairedb
t-test, and the Mann_Whitney nonparametrical
testc. Statistical significance was set
to P < 0.05.
3 Results
3.1 Patients' profile
In both groups, patients were matched for age,
severity of OSA and ED duration. The baseline
characteristics are shown in Table 1. They were also matched for
IIEF domain score before treatment (mean score: 7 for
CPAP-treated and 7.8 for sildenafil-treated).
Comorbidities such as diabetes mellitus, atherosclerosis,
hyper-lipidemia, coronary artery disease and hypertension were
evenly distributed in both groups. In general, 15 of 20
CPAP-treated patients and 14 of 20 sildenafil-treated
patients suffered one or more concomitant diseases. All
patients included in this study were heavy smokers,
at least until recently, and all were also considered overweight.
3.2 Treatment efficacy
Under CPAP, the 20 patients attempted intercourse
for 193 times, with a mean of 9.65 attempts per patient
during the treatment period. Of these attempts, 51
(26.9%) were successful. Under oral sildenafil the 20
patients attempted intercourse for 249 times, with a mean
of 12.45 attempts per patient. Of these attempts, 128
(51.4%) were successful (Figure 1). Patients under
sildenafil made more attempts than patients under CPAP
(mean: 12.5 vs. 9.6; cP = 0.002), and were more
successful (mean: 6.4 and 2.5;
cP < 0.001).
IIEF domain scores were increased in both groups
compared to baseline. In patients under sildenafil, the
EF scores after treatment were higher than before (mean:
14.3 vs. 7.8; aP < 0.001). In patients under CPAP the
EF scores after treatment were also significantly higher
than before (mean: 10.8 and 7.0;
aP = 0.002). However,
after treatment, the group treated with sildenafil showed
a significantly higher mean score of EF than the group
of CPAP (mean: 14.3 vs. 10.8;
bP = 0.025; Table 2).
3.3 Satisfaction with treatment
Overall, 5 of 20 men (25%) were satisfied with CPAP
for the treatment of ED but 10 of 20 men (50%) were
satisfied with sildenafil. Satisfaction with treatment was
significantly higher among the patients under sildenafil
than that in the CPAP group (cP = 0.007). The
corresponding partners' satisfaction rates were 20% with
CPAP and 50% with sildenafil. Satisfaction with
treatment was significantly higher among the partners of the
patients treated with sildenafil than that in the other group
(cP = 0.002). After the analytical assessment of answers
given by the men and their partners, it was concluded
that partners evaluate satisfaction with treatment
differently, but not significantly, from the patients
themselves. However, the satisfaction of patients and
partners with sildenafil was clearly superior to that with
CPAP. Scores of EDITS question 1 are shown in detail
in Table 3.
3.4 Safety
CPAP and sildenafil were well tolerated. Nasal
dryness was reported by four patients under CPAP treatment,
and some episodes common for PDE 5 inhibitors, such
as transient flushing and mild headache, were reported
by three men treated with sildenafil. No adverse events
were significant and no patient required any specific
treatment, nor did they withdraw from the study.
4 Discussion
OSA-related complications, including ED, may be
caused by the coordination of hypoxic episodes, which
are common in sleep apnea, with arousal-related,
end-apneic hyperadrenergic reactions [2]. This mechanism
results in a key event: the reduction in circulating NO
levels which increases platelet aggregation and
vasoconstriction and impairs function of the vascular endothelial
cells [15]. Because smooth muscle relaxation is brought
about by the release of NO from the endothelial cells and
the nerves supplying the erectile tissue, disturbances in
this basic neurovascular event may cause ED.
It has been reported that CPAP treatment significantly
improves subjective and objective sleep parameters in
patients with OSA, and that men with more severe apnea
may benefit more [16]. Consequently, several studies
reported on the efficacy of this therapeutic method in
the treatment of OSA-associated ED. Oxygen therapy
for one month resulted in the reversal of ED in men with
obstructive pulmonary disease [17]. CPAP provided
either in the short term or for 12 weeks improved erectile
function in men with OSA and ED [10, 11]. CPAP also
had a positive impact on ED in the long term (12 weeks);
predictors of erectile improvement were the severity of
OSA (high RDI and low minimum oxygen saturation of
hemoglobin during sleep) and the compliance with CPAP
[18]. The effectiveness of CPAP may be due to the
increase of NO circulating levels and the consequent
improvement of endothelial cell function [15]. Interestingly,
Margel and co-workers [18] reported on a subset of
patients in whom erectile function deteriorated following
CPAP. However, one of the main characteristics of that
subset was non-compliance to CPAP. The treating
physician should be aware of the proper use of the device
and of treatment compliance when assessing CPAP effectiveness.
In the present study, when the mean severity of OSA
was mild, sildenafil proved to be more effective than CPAP
as it resulted in a significantly higher rate of successful
attempts for intercourse and increased IIEF domain scores
compared to CPAP. The direct smooth muscle relaxation
in the penile arteries and corpora cavernosa caused by
sildenafil may explain the higher effectiveness of this
treatment. The higher effectiveness of sildenafil may
consequently explain the higher number of intercourse
attempts, reflecting the men's strengthened self-confidence. However, the effectiveness of sildenafil in
these patients was lower than that generally reported in
men with ED, and in a specific study group of men with
ED [19, 20]. This may be caused by the combination of
smoking abuse and comorbidities, true risk factors for
ED, and by the OSA-related hypoxia, though mild, which
impairs NO's antioxidant function with adverse vascular
consequences. Possibly for these reasons, according to
the IIEF domain scores, the men in this study suffered
from severe ED. Moreover, the sildenafil-treated
patients did not receive specific OSA therapy for three
months. Thus, the apnea-induced daytime somnolence
and the depressed mood commonly seen in patients with
apnea episodes may have negatively affected the quality
of life in these individuals [21], not allowing sildenafil to
work to its full potential.
The satisfaction with treatment results reported in
this study should be interpreted with caution. The small
number of studied patients and the mild severity of
underlying OSA restricted the satisfaction evaluation.
Moreover, the trial was not blind and the different nature
of the two treatments might cause bias. However, the
differences in efficacies reflect on the patients' and their
partners' satisfaction with treatment for ED. It must be
emphasized that all patients treated with sildenafil
succeeded in at least two attempts at intercourse.
Obviously, the patient scores were higher than those of their partners.
This finding likely stems from the different perception
of treatment satisfaction in patients and partners.
Generally, the expectations of women, affected by
intimacy and emotional closeness, are substantially
different from those of the men, who measure success based
on the improvement of the erection. Although sildenafil
was more effective than CPAP in treating ED,
approximately half of the patients were not satisfied with this
treatment. Thus, it seems that none of the studied
therapeutic methods met the needs and expectations of all
patients. It must be noted that satisfaction was not
affected by adverse events, as both therapeutic methods
proved to be safe and well tolerated.
In conclusion, the results of this study suggest
that both therapeutic methods were safe and effective, but
sildenafil was superior to CPAP in the treatment of ED in
men with OSA. Because OSA and comorbidities represent a model of severe endothelial dysfunction, they may
be associated with severe ED as well. This fact possibly
results in a lower effectiveness of sildenafil compared to
that generally observed in men seeking treatment for ED.
Because of the high percentage of dissatisfaction with
both treatments, we conclude that different therapeutic
methods, including combinations of CPAP with sildenafil,
or newer oral agents, should be studied further.
References
1 Young T, Peppard PE, Gottlieb DJ. Epidemiology of
obstructive sleep apnea: a population health perspective. Am J Respir
Crit Care Med 2002; 165: 1217_39.
2 Fanfulla F, Malaguti S, Montagna T, Salvini S, Bruschi C,
Crotti P, et al. Erectile dysfunction in men with obstructive
sleep apnea: an early sign of nerve involvement. Sleep 2000;
23: 775_81.
3 Margel D, Cohen M, Livne PM, Pillar G. Severe, but not
mild, obstructive sleep apnea syndrome is associated with
erectile dysfunction. Urology 2004; 63: 545_9.
4 Guilleminault C, Eldridge FL, Tilkian A, Simmons FB,
Dement WC. Sleep apnea syndrome due to upper airway
obstruction. A review of 25 cases. Arch Intern Med 1977;
137: 296_300.
5 Hirshkowitz M, Karacan I, Gurakar A, Williams RI.
Hypertension, erectile dysfunction, and occult sleep apnea.
Sleep 1989; 12: 223_32.
6 Pressman MR, DiPhillipo MA, Kendrick JI, Conroy K, Fry
JM. Problems in the interpretation of nocturnal penile
tumescence studies: disruption of sleep by occult sleep disorders. J
Urol 1986; 136: 595_8.
7 Lavie P, Herer P, Hoffstein V. Obstructive sleep apnea
syndrome as risk factor for hypertension: population study. Br
Med J 2000; 320: 479_82.
8 Haight JS, Djupesland PG. Nitric oxide (NO) and obstructive
sleep apnea (OSA). Sleep Breath 2003; 7: 53_62.
9 Malhotra A, White DP. Obstructive sleep apnea. Lancet
2002; 360: 237_45.
10 Karacan I, Karatas M. Erectile dysfunction in sleep apnea and
response to CPAP. J Sex Marit Ther 1995; 21: 239_47.
11 Perimenis P, Karkoulias K, Markou S, Gyftopoulos K,
Athanasopoulos A, Barbalias G, et al. Erectile dysfunction in
men with obstructive sleep apnea syndrome: a randomized
study of the efficacy of sildenafil and continuous positive
airway pressure. Int J Impot Res 2004; 16: 256_60.
12 Low WY, Ng CJ, Tan NC, Choo WY, Tan HM. Management
of erectile dysfunction: barriers faced by general practitioners.
Asian J Androl 2004; 6: 99_104.
13 Son H, Park K, Kim SW, Paick JS. Reasons for
discontinuation of sildenafil citrate after successful restoration of erectile
function. Asian J Androl 2004; 6: 117_20.
14 Althof SE, Corty EW, Levine SB, Levine F, Burnett AL,
McVary K, et al. EDITS: development of questionnaires for
evaluating satisfaction with treatment for erectile dysfunction.
Urology 1999; 53: 793_9.
15 Ip MS, Lam B, Chan LY, Zheng LY, Tsang KW, Fung PC,
et al. Circulating nitric oxide is suppressed in obstructive sleep
apnea and is reversed by nasal continuous positive airway
pressure. Am J Respir Crit Care 2000; 162: 2166_71.
16 Patel SR, White DP, Malhotra A, Stanchina ML, Ayas NT.
Continuous positive airway pressure therapy for treating
sleepiness in a diverse population with obstructive sleep apnea:
results of a meta-analysis. Arch Intern Med 2003; 163: 565_71.
17 Aasebo U, Gyltnes A, Bremnes RM, Aakvaag A, Slordal L.
Reversal of sexual impotence in male patients with chronic
obstructive pulmonary disease and hypoxemia with long-term
oxygen therapy. J Steroid Biochem Mol Biol 1993; 46:
799_803.
18 Margel D, Tal R, Livne PM, Pillar G. Predictors of erectile
function improvement in obstructive sleep apnea with
long-term CPAP treatment. Int J Impot Res 2005; 17: 186_90.
19 Perimenis P, Gyftopoulos K, Giannitsas K, Markou SA, Tsota
I, Chrysanthopoulou A, et al. A comparative, crossover study
of the efficacy and safety of sildenafil and apomorphine in
men with evidence of arterial erectile dysfunction. Int J Impot
Res 2004; 16: 2_7.
20 Perimenis P, Markou S, Gyftopoulos K, Giannitsas K,
Athanasopoulos A, Liatsikos E, et al. Efficacy of
apomorphine and sildenafil in men with nonarteriogenic erectile
dysfunction. A comparative crossover study. Andrologia
2004; 36: 106_10.
21 Akashiba T, Kawahara S, Akahoshi T, Omori C, Saito O,
Majima T, et al. Relationship between quality of life and mood
or depression in patients with severe obstructive sleep apnea
syndrome. Chest 2002; 122: 861_5.
|